

IN THE CLAIMS:

Please cancel claims 1-15.

16. An expression vector comprising two inverted terminal repeats of adeno-associated virus 2 and at least one cassette comprising a promoter capable of effecting cell-specific expression, wherein each of said inverted terminal repeats is SEQ ID NO: 1 or a fragment of SEQ ID NO: 1 that comprises nucleotides 1 to 125 of SEQ ID NO: 1, wherein said promoter is operably linked to a heterologous gene, and wherein said cassette resides between said inverted terminal repeats.

17. The vector of claim 16 wherein each of said inverted terminal repeats is SEQ ID NO:1.

18. The vector of claim 16 wherein each of said inverted terminal repeats is a fragment of SEQ ID NO: 1 that comprises nucleotides 1 to 125 of SEQ ID NO:1.

19. The vector of claim 16 wherein said heterologous gene encodes a biologically functional protein.

20. The vector of claim 16 wherein said heterologous gene encodes a non-biologically functional protein.

21. The vector of claim 16 wherein said heterologous gene is a hybrid gene.

22. The vector of claim 16 wherein said heterologous gene is selected from the group consisting of a gene encoding α -globin, β -globin, γ -globin, granulocyte macrophage-colony stimulating factor (GM-CSF), tumor necrosis factor (TNF), any one of interleukins 1-11, neomycin resistance, luciferase, adenine phosphoribosyl transferase (APRT), retinoblastoma, insulin, mast cell growth factor, p53, and adenosine deaminase.

23. The vector of claim 16 wherein said heterologous gene encodes P-glycoprotein.

24. The vector of claim 21 wherein said antisense RNA is complementary to a segment of the DNA or RNA encoding α -globin.

25. The vector of claim 16 wherein said vector is AAV-B19-mdr.

26. A host cell transfected by the vector of any one of claims 16-25.

27. The host cell of claim 26 wherein said cell is a hematopoietic stem or hematopoietic progenitor cell.

28. A virion comprising the vector of any one of claims 16-24.

29. A host cell infected by the virion of claim 28.

30. The host cell of claim 29 wherein said cell is a hematopoietic stem or progenitor cell.

Status of Claims and Support for Changes Made to the Claims:

1-15. (Canceled)

16-30. (Pending)

Support for added claims 16-30 is identified in the Preliminary Amendment filed on July 16, 2003 and the Amendment filed on August 30, 2004. More specifically, the expression vector of claim 16 is supported by claim 1 of the original patent and by the entire specification, e.g., column 17, lines 1-32. Furthermore, the recitation in claim 16 of "wherein each of said inverted terminal repeats is SEQ ID NO: 1 or a fragment of SEQ ID NO: 1 that comprises nucleotides 1 to 125 of SEQ ID NO: 1", is supported by the specification, e.g., on col. 9, lines 41-45, where the text refers to "the 145 nucleotides of FIG. 1" (i.e., SEQ ID NO: 1) and "[f]ragments which contain the 125 nucleotides which form the palindromic hairpin (nucleotide 1-125 of FIG. 1)" (i.e., nucleotide 1-125 of SEQ ID NO: 1). Claims 17-20 and 22-30, which depend from claim 16, are written in essentially the same manner as dependent claims 2-4 and 6-15 of the '834 patent and are supported throughout the specification. Claim 21, which also depends from claim 16, finds support in claim 5 of the '834 patent and in the specification at col. 7, lines 15-19.